Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown
Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown
$200.00
The BCMA CAR-T therapies gap between industry leaders Celgene and bluebird bio and their competition in the space is closing, according to data released at the December 2018 American Society of Hematology (ASH) meeting in San Diego.
Publisher: Scrip
- Description
With an increasing number of companies, including Poseida Therapeutics, Inc., Legend Biotech Corp, and Janssen Pharmaceutical Cos. developing BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapies, market leaders Celgene Corp. and bluebird bio Inc. are seeing their stronghold on the area weaken. Tap into this and other information regarding CAR-T therapies as reported at the December 2018 meeting of the American Society of Hematology (ASH) in San Diego, in this illuminating and data-packed article from Scrip.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Commission Addresses Non-EU/EEA Authorities To Set Record Straight On New EU... 
Sign up to the